See more : Kaira Can Company Limited (KAIRA.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Bellicum Pharmaceuticals, Inc. (BLCM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Bellicum Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Muramoto Electron (Thailand) Public Company Limited (METCO.BK) Income Statement Analysis – Financial Results
- Oi S.A. (OIBR-C) Income Statement Analysis – Financial Results
- H&R Block, Inc. (0HOB.L) Income Statement Analysis – Financial Results
- CTX Virtual Technologies, Inc. (CTXV) Income Statement Analysis – Financial Results
- OPAL Fuels Inc. (OPAL) Income Statement Analysis – Financial Results
Bellicum Pharmaceuticals, Inc. (BLCM)
About Bellicum Pharmaceuticals, Inc.
Bellicum Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen; and BPX-603, a dual-switch GoCAR-T product candidate that is in Phase 1/2 clinical trials to treat solid tumors that express the human epidermal growth factor receptor 2 antigens. Its clinical product candidates also include Rivo-cel, an allogeneic T cell product candidate intended to enhance outcomes in the treatment of leukemias, lymphomas, and inherited blood disorders. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in Houston, Texas.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.50M | 6.20M | 500.00K | 7.14M | 1.12M | 185.00K | 388.00K | 282.00K | 1.78M | 1.94M | 1.47M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 1.50M | 6.20M | 500.00K | 7.14M | 1.12M | 185.00K | 388.00K | 282.00K | 1.78M | 1.94M | 1.47M |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 22.76M | 23.58M | 39.05M | 64.54M | 71.15M | 65.66M | 51.26M | 33.56M | 11.01M | 7.05M | 5.80M |
| General & Administrative | 5.72M | 7.01M | 15.53M | 29.97M | 25.43M | 21.91M | 17.51M | 15.86M | 5.40M | 2.81M | 1.94M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 5.72M | 7.01M | 15.53M | 29.97M | 25.43M | 21.91M | 17.51M | 15.86M | 5.40M | 2.81M | 1.94M |
| Other Expenses | 0.00 | 7.00K | 112.00K | -2.99M | 436.00K | 864.00K | 580.00K | 3.18M | 43.21B | 0.00 | 0.00 |
| Operating Expenses | 28.48M | 30.59M | 54.58M | 94.51M | 96.59M | 87.57M | 68.77M | 49.42M | 16.41M | 9.86M | 7.74M |
| Cost & Expenses | 28.48M | 30.59M | 54.58M | 94.51M | 96.59M | 87.57M | 68.77M | 49.42M | 16.41M | 9.86M | 7.74M |
| Interest Income | 0.00 | 32.00K | 387.00K | 1.35M | 1.64M | 1.06M | 909.00K | 641.00K | 34.98K | 3.92K | 7.55K |
| Interest Expense | 46.00 | 4.00K | 2.66M | 4.28M | 4.20M | 3.67M | 1.76M | 12.00K | 1.76M | 50.72K | 1.41K |
| Depreciation & Amortization | -1.95M | 517.00K | -1.89M | 19.19M | 6.70M | 3.56M | 2.31M | 1.20M | 666.61K | 587.25K | 115.28K |
| EBITDA | -26.98M | -24.35M | 2.39M | -87.36M | -95.47M | -82.77M | -68.38M | -47.30M | -57.84B | -7.33M | -6.15M |
| EBITDA Ratio | -1,928.93% | -392.73% | -10,716.80% | -954.39% | -8,523.75% | -44,739.46% | -17,623.71% | -16,771.28% | -821.69% | -377.75% | -418.02% |
| Operating Income | -26.98M | -24.87M | -51.69M | -87.36M | -95.47M | -87.39M | -68.38M | -49.14M | -57.84M | -7.92M | -6.27M |
| Operating Income Ratio | -1,798.73% | -401.06% | -10,338.40% | -1,223.07% | -8,523.75% | -47,236.22% | -17,623.71% | -17,423.76% | -3,249.33% | -408.21% | -426.37% |
| Total Other Income/Expenses | 2.01M | 15.16M | -10.11M | -25.11M | -2.57M | -4.39M | -861.00K | 587.00K | -26.13M | -46.80K | 6.14K |
| Income Before Tax | -24.97M | -9.71M | -7.72M | -112.48M | -98.04M | -91.78M | -69.24M | -48.55M | -83.97M | -7.97M | -6.26M |
| Income Before Tax Ratio | -1,664.73% | -156.53% | -1,544.40% | -1,574.65% | -8,753.21% | -49,610.27% | -17,845.62% | -17,215.60% | -4,717.13% | -410.62% | -425.96% |
| Income Tax Expense | 2.00K | -127.00K | 897.00K | 13.62M | 1.63M | 3.67M | -1.46M | 12.00K | 1.09M | 3.92K | 7.55K |
| Net Income | -24.97M | -9.58M | -8.62M | -126.09M | -98.04M | -91.78M | -69.24M | -48.55M | -83.97M | -7.97M | -6.26M |
| Net Income Ratio | -1,664.87% | -154.48% | -1,723.80% | -1,765.25% | -8,753.21% | -49,610.27% | -17,845.62% | -17,215.60% | -4,717.13% | -410.62% | -425.96% |
| EPS | -0.81 | -0.83 | -1.50 | -26.92 | -24.37 | -28.94 | -25.69 | -18.43 | -33.47 | -8.11 | -6.37 |
| EPS Diluted | -0.81 | -0.83 | -1.50 | -26.92 | -24.37 | -28.94 | -25.69 | -18.43 | -33.47 | -8.11 | -6.37 |
| Weighted Avg Shares Out | 30.83M | 11.50M | 5.76M | 4.68M | 4.02M | 3.17M | 2.70M | 2.63M | 2.51M | 982.78K | 982.78K |
| Weighted Avg Shares Out (Dil) | 30.83M | 11.50M | 5.76M | 4.68M | 4.02M | 3.17M | 2.70M | 2.63M | 2.51M | 982.78K | 982.78K |
Bellicum Pharmaceuticals: Narrowing The Thesis And Simplifying The Investment
Bellicum Pharmaceuticals, Inc. (BLCM) CEO Richard Fair on Q4 2020 Results - Earnings Call Transcript
Bellicum Reports Fourth Quarter 2020 Financial Results and Provides Operational Update
Bellicum to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update
BLCM Stock Price Increases Over 15% Pre-Market: Why It Happened
Bellicum Announces First Reported Use of CaspaCIDe® Safety Switch to Mitigate CAR-T Cell Toxicity
BLCM Stock Price Increases Over 40% Pre-Market: Why It Happened
Bellicum Reports FDA Lifted Clinical Hold on BPX-601 Phase 1/2 Clinical Trial
Bet on Rising P/E With These 5 Top-Ranked Stocks
Bellicum Pharmaceuticals (BLCM) Upgraded to Buy: Here's Why
Source: https://incomestatements.info
Category: Stock Reports